Literature DB >> 17640155

Safety and tolerability of antidepressants: weighing the impact on treatment decisions.

Alan F Schatzberg1.   

Abstract

Major depressive disorders affect an estimated 23 million U.S. adults per year. While antidepressants are effective in improving the symptoms of depression, side effects are an undesirable outcome of treatment and can have an impact on patient adherence to treatment. Compared with older drugs, selective serotonin reup-take inhibitors, serotonin-norepinephrine reuptake inhibitors, and other antidepressants have more benign side effect profiles. Research continues to elucidate new agents that may combine efficacy with a minimum of side effects, as well as new methods of predicting individual response to particular antidepressants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640155

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

1.  Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.

Authors:  Lauren D Garfield; David Dixon; Petra Nowotny; Francis E Lotrich; Bruce G Pollock; Sean D Kristjansson; Peter M Doré; Eric J Lenze
Journal:  Am J Geriatr Psychiatry       Date:  2013-09-08       Impact factor: 4.105

Review 2.  Desvenlafaxine extended release.

Authors:  Lily P H Yang; Greg L Plosker
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3.

Authors:  Hai-Shui Shi; Wei-Li Zhu; Jian-Feng Liu; Yi-Xiao Luo; Ji-Jian Si; Shen-Jun Wang; Yan-Xue Xue; Zeng-Bo Ding; Jie Shi; Lin Lu
Journal:  Neuropsychopharmacology       Date:  2012-07-25       Impact factor: 7.853

4.  Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.

Authors:  Michael R Liebowitz; Karen A Tourian
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

5.  Introduction: chronic medical conditions and depression--the view from primary care.

Authors:  Richard L Kravitz; Daniel E Ford
Journal:  Am J Med       Date:  2008-11       Impact factor: 4.965

6.  Duloxetine for the management of fibromyalgia syndrome.

Authors:  Beth A Scholz; Cara L Hammonds; Chad S Boomershine
Journal:  J Pain Res       Date:  2009-07-21       Impact factor: 3.133

Review 7.  Changes in body weight and psychotropic drugs: a systematic synthesis of the literature.

Authors:  Robert Dent; Angelique Blackmore; Joan Peterson; Rami Habib; Gary Peter Kay; Alan Gervais; Valerie Taylor; George Wells
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

8.  Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial.

Authors:  John Papastergiou; Lena C Quilty; Wilson Li; Thulasi Thiruchselvam; Esha Jain; Peter Gove; Leilany Mandlsohn; Bart van den Bemt; Nedzad Pojskic
Journal:  Clin Transl Sci       Date:  2021-02-28       Impact factor: 4.689

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.